A recent study testing the impact of microdosing LSD has suggested the practice has no therapeutic or cognitive effects.
A group of scientists have reported findings that provide a foundation for the structure-based design of safe and effective non-hallucinogenic, rapid-acting antidepressants.
A new narrative review of systematic evidence has been published by leading researchers at Drug Science to get the facts on the adverse effects of classic...
MindMed is expected to begin enrolling patients immediately into its proof-of-concept exploratory trial for the use of LSD to treat adult ADHD.
BetterLife Pharma has announced its first set of positive data showing the anti-depressant effects of an LSD derivative – 2-bromo-LSD (TD-0148A).
A new study has been launched to investigate the effects of LSD microdosing on sleep and cognitive measures.
A group of experts gathered to discuss microdosing, and separate the fact from the fiction on the safety and efficacy of the practice.
Researchers have discovered changes in the brain associated with LSD which they say could help gain insights into how the brain generates behaviour.
Better Life Pharma has obtained its first set of data on its lead compound TD-0148A, a second-generation LSD derivative, with further preclinical studies underway to determine...
Mind Medicine has presented its novel findings on LSD and psilocybin from several ongoing studies.